CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial

By sjmartinez • December 18, 2024

Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial. Leuk Lymphoma. 2024 Dec 17:1-7. doi: 10.1080/10428194.2024.2438809. Epub ahead of print. PMID: 39689718.

Tags: AML, CPX-351, Fellow, gemtuzumab ozogamicin, Hematology/Oncology, Publications

IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

Jiang H, Limsuwannarot S, Kulhanek KR, Pal A, Labiad O, Rysavy LW, Wong A, Su L, Cavender S, Soro J, Testa S, Ogana H, Waghray[...]

Mammary small cell neuroendocrine carcinomas that showed excellent pathologic response following etoposide-based neoadjuvant chemotherapy

Hammer PM, Enamandram S, Ikeda DM, Lam MM, Wapnir IL, Chamberlain ED, Shaheen S, Caswell-Jin JL, Itakura H, Bean GR. Mammary small cell neuroendocrine carcinomas[...]

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis

Zaorsky NG, Sun Y, Nabid A, Zapatero A, Bolla M, Joseph D, Maingon P, Guerrero A, Gonzalez AA, San-Segundo CG, Cabeza Rodríguez MÁ, Sole JM,[...]